Subscribe
A worldwide window to Cambridge business, innovation and technology
International investors back Maxion Therapeutics in $72m Series A raise

International investors back Maxion Therapeutics in $72m Series A raise

Cambridge biotech Maxion Therapeutics has raised $72 million (£58m) in a Series A financing to further grow the business worldwide. The company is developing antibody-based KnotBody® drugs for ion channel and G protein coupled receptor (GPCR)-driven diseases.
AstraZeneca paying up to $1bn for Belgian cancer company EsoBiotec

AstraZeneca paying up to $1bn for Belgian cancer company EsoBiotec

AstraZeneca, headquartered in Cambridge, could pay up to $1 billion on a cash and debt-free basis for Belgian company EsoBiotec to advance its cell therapy ambitions.
Orion Corporation to open Biologics R & D centre in Cambridge

Orion Corporation to open Biologics R & D centre in Cambridge

Quoted Finnish pharmaceutical company Orion Corporation is establishing a new research & development centre in Cambridge to accelerate its global growth strategy and the development of innovative medicines.
‘Nuclear’ invention cuts travel time to Mars in half

‘Nuclear’ invention cuts travel time to Mars in half

Pulsar Fusion in Bletchley has brought space propulsion technology out of stealth with the unveiling of Sunbird, a nuclear fusion rocket concept developed in complete secrecy over the past decade.
bit.bio clears the way for next phase of growth

bit.bio clears the way for next phase of growth

bit.bio, one of the Cambridge life science cluster’s most exciting companies, has gone through a huge overhaul in the boardroom – including a change of CEO – in a matter of weeks as it bids to underpin long-term prosperity and success.
Academia
Sharewatch
Manufacturing
Entrepreneurship programme for women launched at Murray Edwards College
12 Mar 2025 - 12:00
Brains in bloom: Sainsbury Laboratory debuts at Chelsea Flower Show
11 Mar 2025 - 12:00
Brain gain milestone as Cambridge Enterprise drives 41 University investments in a year
10 Mar 2025 - 12:00

Business awards

Entries now being accepted

Business directory

Browse our listings of Cambridge companies

The killer 50

The 50 hottest disruptive technology companies

News

International investors back Maxion Therapeutics in $72m Series A raise

International investors back Maxion Therapeutics in $72m Series A raise

Cambridge biotech Maxion Therapeutics has raised $72 million (£58m) in a Series A financing to further grow the business worldwide. The company is developing antibody-based KnotBody® drugs for ion channel and G protein coupled receptor (GPCR)-driven diseases.
AstraZeneca paying up to $1bn for Belgian cancer company EsoBiotec

AstraZeneca paying up to $1bn for Belgian cancer company EsoBiotec

AstraZeneca, headquartered in Cambridge, could pay up to $1 billion on a cash and debt-free basis for Belgian company EsoBiotec to advance its cell therapy ambitions.
Delivering a Net Zero Strategy for Growth Companies

Delivering a Net Zero Strategy for Growth Companies

Achieving net zero – or balancing greenhouse gas (GHG) emissions with their removal – is a key strategic priority for UK growth-stage businesses, writes Paul Hughes – Managing Director, Life Sciences & Technology – at BDO LLP.
Region’s manufacturers’ strong start to year defies UK gloom

Region’s manufacturers’ strong start to year defies UK gloom

East of England manufacturers have seen a strong start to 2025 according to the latest survey from Make UK and BDO and are set to translate this confidence into jobs.
More news

Tech trail

International investors back Maxion Therapeutics in $72m Series A raise

International investors back Maxion Therapeutics in $72m Series A raise

Cambridge biotech Maxion Therapeutics has raised $72 million (£58m) in a Series A financing to further grow the business worldwide. The company is developing antibody-based KnotBody® drugs for ion channel and G protein coupled receptor (GPCR)-driven diseases.
ImmuONE raises £600K to advance human lung model as alternative to animal drug testing

ImmuONE raises £600K to advance human lung model as alternative to animal drug testing

An East of England biotech start-up with a 3D human lung model that provides an alternative to animal testing has raised a further £600k growth capital from the Midlands Engine Investment Fund, Mercia Ventures and Pioneer Group.
Cambridge central to ClariMed’s global expansion strategy

Cambridge central to ClariMed’s global expansion strategy

Strategic acquisitions on both sides of the Atlantic – in Cambridge UK and California US – laid the foundations for global growth for innovative MedTech-focused company ClariMed.
TRIMTECH raises $31m from Cambridge UK and US backers

TRIMTECH raises $31m from Cambridge UK and US backers

Cambridge biotech TRIMTECH Therapeutics, which is harnessing targeted protein degradation for the treatment of neurodegenerative diseases, has closed an oversubscribed $31 million (£25m) seed round featuring a number of US investors.
More Tech trail

Trade floor

AstraZeneca paying up to $1bn for Belgian cancer company EsoBiotec

AstraZeneca paying up to $1bn for Belgian cancer company EsoBiotec

AstraZeneca, headquartered in Cambridge, could pay up to $1 billion on a cash and debt-free basis for Belgian company EsoBiotec to advance its cell therapy ambitions.
42 Technology and partners unveil new AI-powered pharma line clearance solution

42 Technology and partners unveil new AI-powered pharma line clearance solution

42 Technology has joined forces with industry leaders in machine vision, edge AI silicon and software – Balluff, Synaptics and Arcturus Networks – to help develop and demonstrate a breakthrough approach for AI-powered automated line clearance in pharmaceutical manufacturing.
Sunny future tipped for tanning firm after MBO

Sunny future tipped for tanning firm after MBO

A management team has taken over Power Tan Ltd in Bedfordshire to set the stage for further growth and international expansion for the indoor tanning business.
Cambridge triple role in superfast 5G project

Cambridge triple role in superfast 5G project

Cambridge Consultants and city colleagues at Stratospheric Platforms Ltd and Marshall were in a five-firm consortium honoured for their role in ’Project Skymast’, which aims to deliver superfast 5G to every corner of the globe from the stratosphere.
Nxera Pharma clinches millions from autoimmune disease deal

Nxera Pharma clinches millions from autoimmune disease deal

Nxera Pharma, with major operations in Cambridge and Tokyo, has negotiated a lucrative deal in the autoimmune diseases space in Asia-Pacific.
More Trade floor